Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
F648447-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$170.90
|
|
|
F648447-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$270.90
|
|
|
F648447-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$550.90
|
|
|
F648447-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$870.90
|
|
|
F648447-100mg
|
100mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,380.90
|
|
| Synonyms | MFCD28053502 | DTXSID9026184 | SCHEMBL4889246 | EX-A2059 | N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide mesylate | N-methyl-N-nitrosouree | Q27271825 | 95Y8L63NBC | DTXS |
|---|---|
| Specifications & Purity | ≥99% |
| Biochemical and Physiological Mechanisms | Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl . Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC 50 values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylati |
| Storage Temp | Store at 2-8°C,Desiccated |
| Shipped In |
Wet ice This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl . Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC 50 values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model In Vitro Flumatinib mesylate (HH-GV-678) (0-1000 μM; 4, 7 and 10 days) blocks cellular Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation in K562 leukemia cells. Flumatinib mesylate (HH-GV-678) (0-10 μM; 72 hours) remarkably decreases the number of cells in chronic myelogenous leukemia cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Chronic myelogenous leukemia cell line Concentration: 0-10 μM Incubation Time: 72 hours Result: The proliferation inhibitory activity was 32-to 58-fold more potent than that of imatinib and 2-to 5-fold more potent than that of nilotinib. Western Blot AnalysisCell Line: K562 cells Concentration: 0, 1, 3, 10, 30, 100, 300 and 1000 μM Incubation Time: 4, 7 and 10 days Result: Suppressed cellular Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. In Vivo Flumatinib mesylate (HH-GV-678) (18-75 mg/kg; p.o.; Twice daily, for 14 days.) inhibits tumor growth in nude mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Nude mice (subcutaneously injecting K562 cells) Dosage: 18.75, 37.5, 75 mg/kg Administration: Oral administration; Twice daily, for 14 days. Result: Inhibited the growth of K562 xenografts in a dose-dependent manner and induced regression in all tumors at a daily dose of 75 mg/kg for nine days. Form:Solid IC50& Target:PDGFRβ 307.6 nM (IC 50 ) c-Abl 1.2 nM (IC 50 ) |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Class | Diazines |
| Subclass | Pyrimidines and pyrimidine derivatives |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Pyridinylpyrimidines |
| Alternative Parents | Trifluoromethylbenzenes Benzamides Phenylmethylamines Benzoyl derivatives Benzylamines Aminopyridines and derivatives Aminopyrimidines and derivatives Aralkylamines Methylpyridines N-methylpiperazines Alkanesulfonic acids Sulfonyls Organosulfonic acids Heteroaromatic compounds Methanesulfonates Amino acids and derivatives Secondary carboxylic acid amides Trialkylamines Secondary amines Azacyclic compounds Organooxygen compounds Hydrocarbon derivatives Alkyl fluorides Organofluorides Organic oxides |
| Molecular Framework | Not available |
| Substituents | Pyridinylpyrimidine - Trifluoromethylbenzene - Benzamide - Benzoic acid or derivatives - Benzoyl - Benzylamine - Phenylmethylamine - Aminopyridine - Aminopyrimidine - Methylpyridine - N-methylpiperazine - N-alkylpiperazine - Aralkylamine - Benzenoid - Monocyclic benzene moiety - 1,4-diazinane - Piperazine - Pyridine - Alkanesulfonic acid - Sulfonyl - Methanesulfonate - Organosulfonic acid - Organosulfonic acid or derivatives - Heteroaromatic compound - Organic sulfonic acid or derivatives - Secondary carboxylic acid amide - Amino acid or derivatives - Tertiary amine - Tertiary aliphatic amine - Carboxamide group - Secondary amine - Azacycle - Carboxylic acid derivative - Organosulfur compound - Alkyl halide - Amine - Organic oxide - Organic oxygen compound - Organohalogen compound - Organic nitrogen compound - Hydrocarbon derivative - Alkyl fluoride - Organofluoride - Organonitrogen compound - Organooxygen compound - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond. |
| External Descriptors | Not available |
|
|
|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide |
|---|---|
| INCHI | InChI=1S/C29H29F3N8O.CH4O3S/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40;1-5(2,3)4/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38);1H3,(H,2,3,4) |
| InChIKey | ZSASDYCFROUKTJ-UHFFFAOYSA-N |
| Smiles | CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O |
| Isomeric SMILES | CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O |
| PubChem CID | 46910592 |
| Molecular Weight | 658.7 |
| Solubility | H2O : 50 mg/mL (75.91 mM; Need ultrasonic) DMSO : 50 mg/mL (75.91 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 658.700 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 7 |
| Exact Mass | 658.23 Da |
| Monoisotopic Mass | 658.23 Da |
| Topological Polar Surface Area | 162.000 Ų |
| Heavy Atom Count | 46 |
| Formal Charge | 0 |
| Complexity | 934.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 2 |